A Snapshot on the Development of Quinolones and Fluoroquinolones - An Origin of Nalidixic Acid
Abstract
Quinolone antibacterial molecules are the most impactful types of anti-infective, active pharmaceutical ingredients in our never-ending battle against pathogens. Additionally, in contrast to many anti-infective classes, the discoverers published a startlingly small amount of information regarding the origin of the class or the justification for this significant group's first FDA-approved agent, nalidixic acid. With an emphasis on the Quantitative Structure-Activity Relationship (QSAR), chemistry, development, adverse effect, and future aspects of this class of antibiotics, this article discusses the discovery, total synthetic methods, pharmacology, clinical applications, and further lead to the new pipeline that produced various large selling and widely used antibiotics.References
Duran-Reynals ML. The fever bark tree: the pageant of quinine. 1st ed. New York, Doubleday & Company Inc., 1946.
Lesher GY, Gruett MD, Baily JH, Brundage PR.. 1,8-Naphtyridine derivatives. A new class of chemotherapeutic agents. J Med Pharm Chem 1962; 91: 1063-65.
Musiol R, Magdziarz T, Kurczyk A. Quinoline scaffold as a privileged substructure in antimicrobial drugs. In Mendez-Vilas A, editor: Science against microbial pathogens: communicating current research and technological advances. 2011; 72-83.
Oliva A, Meepagala KM, David E, Harries D, Hale AL, Aliotta G, Duke SO. Natural fungicides from Ruta graveolens L. leaves, including a new quinolone alkaloid. J. Agric. Food Chem. 2003; 51 (4): 890-896.
Takahashi H, Hayakawa I, Akimoto T. The history of the development and changes of quinolone antibacterial agents. Yakushigaku Zasshi 2003; 38(2):161-79.
Sivakumar M et.al, Antibacterial. Narosa Publishing House: Delhi, 2010; Vol. sixth reprint.
Nakatsu T, Johns T, Kubo I, Milton K, Sakai M, Chatani K et. al. Isolation, structure, and synthesis of novel 4-quinolinone alkaloids from Esenbeckia leiocarpa. J. Nat. Prod. 1990; 53 (6):1508-1513.
Emmerson AM, Jones AM. The quinolones: decades of development and use. J. Antimicrob. Chemother. 2003; 51: 13-20.
Rusu A, Lungu IA, Moldovan OL, Tanase C, Hancu G. Structural Characterization of the Millennial Antibacterial (Fluoro) Quinolones-Shaping the Fifth Generation. Pharmaceutics 2021; 13:1289.
Van Bambeke F, Michot JM., Van Eldere J, Tulkens PM. Quinolones in 2005: an update. Clin Microbiol Infect 2005; 11: 256-280.
Thu D, Ziora ZM, Blaskovich MAT. Quinolone antibiotics. Med. Chem. Commun. 2019; 10:1719 –1739.
Bush NG, Diez-Santos I, Abbott LR, Maxwell A. Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance. Molecules 2020; 25:5662-89.
Tillotson GS. Quinolones: structure-activity relationships and future predictions. J. Med. Microbiol. 1996; 44 (5): 320-324.
Barry AL. In-vitro activity of the fluoroquinolone compounds. Antimicrobic Newsletter 1988; 5 (10): 69-76.
Saravolatz LD, Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin. Infect. Dis. 2003; 37 (9): 1210-1215.
Goldstein EJC. Norfloxacin, a fluoroquinolone antibacterial agent: classification, mechanism of action, and in vitro activity. Am. J. Med. 1987; 82 (6): 3-17.
Dougherty TJ, Beaulieu D, Barrett JF. New quinolones and the impact on resistance. Drug Discov 2001; 6 (10): 529-536.
Blandeau JM. Expanded activity and utility of the new fluoroquinolones: A review. Clin. Ther 1999;21 (1): 3-40.
Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int. J. Antimicrob. Agents 2000; 16(1): 5-15.
Newton ER, Akerman AW, Strassle PD et al. Association of Fluoroquinolone Use with Short-term Risk of Development of Aortic Aneurysm. JAMA Surg. 2021; 156(3): 264-272. doi:10.1001/jamasurg.2020.6165
Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012; 75 (3): 311-335.
Bhatnagar K, Wong A. The mutational landscape of quinolone resistance in Escherichia coli. PLoS ONE 2019, 14(11): e0224650.
Brar RK, Jyoti U, Patil RK, Patil HC. Fluoroquinolone antibiotics: An overview. Adesh Univ J Med Sci Res 2020; 2(1): 26-30
Bisacchi GS. Origins of the Quinolone Class of Antibacterials: An Expanded “Discovery Story”. J. Med. Chem. 2015; 58: 4874−4882.
The HC, Boinett C, Thanh DP, Jenkins C, Weill F, Howden BP. Dissecting the molecular evolution of fluoroquinolone-resistant Shigella sonnei. Nat. Commun. 2019; 10: 4828-41.
Mustaev, A., Malik, M., Zhao, X., Kurepina, N., Luan, G., Oppegard, L. M., Hiasa, H., Marks, K. R., Kerns, R. J., Berger, and J. M., Drlica, K. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding. J. Biol. Chem. 2014; 289: 12300-12312
Pandey, A., Aggarwal, N., Adholeya, A., & Kochar, M. Resurrection of nalidixic acid: evaluation of water-based nanoformulations as potential nanomedicine. Nanoscale research letters 2018; 13(1): 1-16.
Ajmal, G., Yadav, N., Kumawat, M.K., Sharma, M.K., Iqbal, M.R. Application of Electrospun Nanofiber in Wound Healing: Trends and Recent Patents Analysis: Life Science-Medicine. Int J Life Sci Pharm Res 2022; 13: L37-L47.
Kumawat, M.K., Sharma, M.K., Yadav, N., Singh, B. 4-Aminoquinolines as Antimalarial Agents: Review of A Medicinal Chemistry Perspective: Pharmaceutical Science-Pharmaceutics. Int J Life Sci Pharm Res 2022; 13: 83-97.
Yadav, N., Rani, S., Sharma, M.K., Kumawat M.K., Diwan, A. Pharmaceutical applications of RS: an overview. UPJOZ 2021; 42(24): 1335–1343.
Kumar, N., Sharma, M.K., Kumawat M.K., Molecular docking study of selected phytochemicals with covid-19 main protease. UPJOZ 2021; 42(24): 1265–1285
Yadav, N., Diwan, A., Sharma, M.K., Ajmal, G., Kumawat, M.K. Biological activity of rice straw-derived materials: an overview. UPJOZ 2021; 42(24): 1256–1264.
Sharma, M.K., Yadav, N., Kumawat, M.K., Iqbal, M. R. The significance of urotensin-II receptor in cardiovascular diseases. UPJOZ 2021; 42: 1438-1447.
Kumawat, M.K., Sharma, M.K., Yadav, N., Singh, B. 4-Aminoquinolines as Antimalarial Agents: Review of a Medicinal Chemistry Perspective: Pharmaceutical Science-Pharmaceutics. Int J Life Sci Pharm Res 2022; 13: 83-97.
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation. Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This work is licensed under a Creative Commons license (CC-BY). However, the license permits any user to read, copy, redistribute and and make derivative the material in any medium or format for any purpose, even commercially.
